SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of ...

Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

EAST WINDSOR, N.J.--(BUSINESS WIRE)--October 20, 2008--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative treatments based on the NexACT ® technology, announced today that it met with the Food and ...

My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about APRI -- Potential Market Size for Vitaros® for Erectile Dysfunction in ...

announced today its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction in Switzerland, with Swissmedic, the Swiss Agency for Therapeutic Products. "We ...

An Israeli pharmaceutical and consumer health products company has agreed to sell Vitaros, an erectile dysfunction cream made by Apricus Biosciences, in that country and the Palestinian Territories, ...

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...